{"totalCount":3,"studies":[
{"protocolSection":{"identificationModule":{"nctId":"NCT06173505","orgStudyIdInfo":{"id":"XmAb717-06"},"organization":{"fullName":"Xencor, Inc.","class":"INDUSTRY"},"briefTitle":"Study of Vudalimab or Pembrolizumab in Combination With Chemotherapy as First-line Treatment in Patients With Advanced NSCLC","officialTitle":"A Phase 1b/2, Open-label, Randomized Study of Vudalimab in Combination With Chemotherapy or Pembrolizumab in Combination With Chemotherapy as First-line Treatment in Patients With Advanced Non-small Cell Lung Cancer"},"statusModule":{"statusVerifiedDate":"2024-12","overallStatus":"RECRUITING","startDateStruct":{"date":"2023-12-27","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2026-10","type":"ESTIMATED"},"completionDateStruct":{"date":"2027-10","type":"ESTIMATED"},"studyFirstSubmitDate":"2023-11-13","studyFirstSubmitQcDate":"2023-12-07","studyFirstPostDateStruct":{"date":"2023-12-15","type":"ACTUAL"},"lastUpdateSubmitDate":"2024-12-02","lastUpdatePostDateStruct":{"date":"2024-12-04","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Xencor, Inc.","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":true,"isFdaRegulatedDrug":true,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"The purpose of this study is to identify the recommended dose of vudalimab to be used in combination with chemotherapy (Part 1) and to evaluate the efficacy and safety of vudalimab plus standard of care chemotherapy relative to pembrolizumab plus chemotherapy (Part 2) as first-line treatment in patients with nonsquamous non-small cell lung cancer (NSCLC).","detailedDescription":"This is a Phase 1b/2 study, multicenter, open-label, randomized study in patients with nonsquamous non-small cell lung cancer without prior treatment for metastatic disease. Part 1 is designed to identify the recommended Phase 2 dose (RP2D) of vudalimab, an anti-PD-1/CTLA-4 bispecific antibody, in combination with standard of care (SOC) chemotherapy. Part 2 will evaluate the efficacy and safety vudalimab, at the RP2D, plus SOC relative to pembrolizumab (anti-PD-1) plus SOC chemotherapy."},"conditionsModule":{"conditions":["Nonsquamous Non-small Cell Lung Cancer"],"keywords":["Non-small cell lung cancer","Nonsquamous","XmAb20717","vudalimab","anti-PD-1 x anti-CTLA-4","checkpoint inhibitor","chemotherapy"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE1","PHASE2"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"SINGLE_GROUP","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":168,"type":"ESTIMATED"}},"armsInterventionsModule":{"armGroups":[{"label":"Vudalimab + Carboplatin + Pemetrexed","type":"EXPERIMENTAL","interventionNames":["Combination Product: Vudalimab + Carboplatin + Pemetrexed"]},{"label":"Pembrolizumab + Carboplatin + Pemetrexed","type":"ACTIVE_COMPARATOR","interventionNames":["Combination Product: Pembrolizumab + Carboplatin + Pemetrexed"]}],"interventions":[{"type":"COMBINATION_PRODUCT","name":"Vudalimab + Carboplatin + Pemetrexed","description":"Vudalimab intravenous + carboplatin intravenous + pemetrexed intravenous","armGroupLabels":["Vudalimab + Carboplatin + Pemetrexed"]},{"type":"COMBINATION_PRODUCT","name":"Pembrolizumab + Carboplatin + Pemetrexed","description":"Pembrolizumab intravenous + carboplatin intravenous + pemetrexed intravenous","armGroupLabels":["Pembrolizumab + Carboplatin + Pemetrexed"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Part 1: Recommended Phase 2 dose of vudalimab in combination with chemotherapy","description":"Incidence of treatment-emergent adverse events and treatment-related adverse events leading to discontinuation of treatment","timeFrame":"Day 1 to Day 21"},{"measure":"Part 2: Progression free survival","description":"Progressive disease per RECIST 1.1 or death, whichever comes first","timeFrame":"Day 1 to 2.5 years"}],"secondaryOutcomes":[{"measure":"Antitumor activity","description":"Objective response rate as determined by investigator, duration of response (Part 1 and Part 2)","timeFrame":"Day 1 to 1.4 years"},{"measure":"Changes in circulating tumor DNA (ctDNA)","description":"Examine ctDNA changes as a surrogate marker for disease burden (Part 1 and Part 2)","timeFrame":"Day 1 to 1.4 years"},{"measure":"Maximum Serum Drug Concentration (Cmax)","description":"(Part 1 and Part 2)","timeFrame":"Day 1 to 1.4 years"},{"measure":"Trough Serum Drug Concentration (Ctrough)","description":"(Part 1 and Part 2)","timeFrame":"Day 1 to 1.4 years"},{"measure":"Area Under the Concentration-time Curve (AUC)","description":"(Part 1 and Part 2)","timeFrame":"Day 1 to 1.4 years"},{"measure":"Overall survival","description":"Time to death from any cause (Part 2)","timeFrame":"Day 1 to 2.5 years"},{"measure":"Incidence of treatment-emergent adverse events","timeFrame":"Time Frame: Day 1 to 1.4 years]"}]},"eligibilityModule":{"eligibilityCriteria":"Key Inclusion Criteria:\n\n* Histologically confirmed, locally advanced (unresectable) or metastatic nonsquamous NSCLC\n* Documented absence of tumor activating EGFR mutation, ALK gene and ROS1 rearrangements, and alterations in any actionable driver oncogenes for which there are locally approved targeted first-line therapies\n* PD-L1 IHC testing documenting TPS \\< 49%\n* No prior systemic treatment for advanced/metastatic NSCLC.\n* Measurable disease by RECIST 1.1\n* ECOG performance status score of 0 or 1\n* Life expectancy ≥ 3 months\n* Adequate liver, kidney, thyroid and bone marrow function\n\nKey Exclusion Criteria:\n\n* Have known active central nervous system metastases and/or carcinomatous meningitis. Patients with treated brain metastases may participate, provided they are radiologically stable\n* Active known or suspected autoimmune disease\n* Has any condition requiring systemic treatment with corticosteroids, prednisone equivalents, or other immunosuppressive medications within 14 days prior to first dose of study drug\n* Interstitial lung disease that is symptomatic\n* Known human immunodeficiency virus (HIV) positive with CD4+ T-cell (CD4+) count \\< 350 cells/μL, or an HIV viral load greater than 400 copies/mL, or a history of an acquired immunodeficiency syndrome-defining opportunistic infection within the past 12 months, or not on established antiretroviral therapy (ART) for at least 4 weeks prior to initiation of study drug dosing. (HIV positive subjects who do not meet these exclusion criteria are eligible)\n* Positive test for hepatitis C RNA (a patient who is hepatitis C virus \\[HCV\\] antibody positive but HCV RNA negative due to documented, curative prior antiviral treatment or natural resolution is eligible)\n* Positive test for hepatitis B surface antigen or hepatitis B core antibody (hBcAb) (a patient whose hBsAg is negative and hBcAb is positive may be enrolled if a hepatitis B virus (HBV) DNA test is negative and the subject is retested for HbsAg and HBV DNA every 2 months)\n* History or evidence of any clinically unstable/uncontrolled disorder, condition, or disease (including, but not limited to, cardiopulmonary, renal, metabolic, hematologic, or psychiatric) other than NSCLC, that, in the opinion of the Investigator, would pose a risk to patient safety or interfere with study evaluations, procedures, or completion\n\nOther protocol defined inclusion/exclusion criteria apply.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"centralContacts":[{"name":"Michael Chiarella","role":"CONTACT","phone":"1-858-945-2415","email":"mchiarella@xencor.com"}],"overallOfficials":[{"name":"Jolene Shorr","affiliation":"Executive Director, Clinical Development","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"Palo Verde Cancer Specialists","status":"RECRUITING","city":"Glendale","state":"Arizona","zip":"85304","country":"United States","geoPoint":{"lat":33.53865,"lon":-112.18599}},{"facility":"Western Regional Medical Center","status":"RECRUITING","city":"Goodyear","state":"Arizona","zip":"85338","country":"United States","geoPoint":{"lat":33.43532,"lon":-112.35821}},{"facility":"Cancer and Blood Specialty Clinic","status":"RECRUITING","city":"Los Alamitos","state":"California","zip":"90720","country":"United States","geoPoint":{"lat":33.80307,"lon":-118.07256}},{"facility":"Eastern Connecticut Hematology and Oncology Associates","status":"RECRUITING","city":"Norwich","state":"Connecticut","zip":"06360","country":"United States","geoPoint":{"lat":41.52426,"lon":-72.07591}},{"facility":"Mid Florida Hematology and Oncology Center","status":"RECRUITING","city":"Orange City","state":"Florida","zip":"32763","country":"United States","geoPoint":{"lat":28.94888,"lon":-81.29867}},{"facility":"Memorial Cancer Institute at Memorial Hospital West","status":"RECRUITING","city":"Pembroke Pines","state":"Florida","zip":"33038","country":"United States","geoPoint":{"lat":26.00315,"lon":-80.22394}},{"facility":"Midwestern Regional Medical Center","status":"RECRUITING","city":"Zion","state":"Illinois","zip":"600099","country":"United States","geoPoint":{"lat":42.44613,"lon":-87.83285}},{"facility":"Johns Hopkins Sidney Kimmel Comprehensive Cancer Center","status":"RECRUITING","city":"Baltimore","state":"Maryland","zip":"21224","country":"United States","geoPoint":{"lat":39.29038,"lon":-76.61219}},{"facility":"Minnesota Oncology Hematology, P.A.","status":"RECRUITING","city":"Maple Grove","state":"Minnesota","zip":"55369","country":"United States","geoPoint":{"lat":45.07246,"lon":-93.45579}},{"facility":"Nebraska Methodist Hospital","status":"RECRUITING","city":"Omaha","state":"Nebraska","zip":"68114","country":"United States","geoPoint":{"lat":41.25626,"lon":-95.94043}},{"facility":"New Jersey Center for Cancer Research","status":"WITHDRAWN","city":"Brick","state":"New Jersey","zip":"08724","country":"United States","geoPoint":{"lat":40.05928,"lon":-74.13708}},{"facility":"Cancer Institute at Phelps","status":"RECRUITING","city":"Sleepy Hollow","state":"New York","zip":"10591","country":"United States","geoPoint":{"lat":41.08565,"lon":-73.85847}},{"facility":"Consultants in Medical Oncology and Hematology, P.C.","status":"RECRUITING","city":"Broomall","state":"Pennsylvania","zip":"19044","country":"United States","geoPoint":{"lat":39.9815,"lon":-75.35658}},{"facility":"Alliance Cancer Specialists","status":"RECRUITING","city":"Horsham","state":"Pennsylvania","zip":"19044","country":"United States","geoPoint":{"lat":40.17844,"lon":-75.12851}},{"facility":"Hematology Associates of Fredericksburg","status":"RECRUITING","city":"Fredericksburg","state":"Virginia","zip":"22408","country":"United States","geoPoint":{"lat":38.30318,"lon":-77.46054}},{"facility":"Jessa Ziekenhuis - Campus Virga Jesse","status":"RECRUITING","city":"Hasselt","zip":"3500","country":"Belgium","geoPoint":{"lat":50.93106,"lon":5.33781}},{"facility":"Athens Medical Center","status":"RECRUITING","city":"Athens","zip":"15125","country":"Greece","geoPoint":{"lat":37.98376,"lon":23.72784}},{"facility":"St. Lukes (Agios Loucas) Hospital","status":"RECRUITING","city":"Thessaloniki","zip":"552 36","country":"Greece","geoPoint":{"lat":40.64072,"lon":22.93493}},{"facility":"Hospital Canselor Tuanku Muhriz","status":"RECRUITING","city":"Cheras","zip":"56000","country":"Malaysia","geoPoint":{"lat":3.108,"lon":101.726}},{"facility":"Pantai Hospital Ipoh","status":"RECRUITING","city":"Ipoh","zip":"31400","country":"Malaysia","geoPoint":{"lat":4.5841,"lon":101.0829}},{"facility":"Hospital Sultan Ismail","status":"RECRUITING","city":"Johor Bahru","zip":"81100","country":"Malaysia","geoPoint":{"lat":1.4655,"lon":103.7578}},{"facility":"Hospital Umum Sarawak","status":"RECRUITING","city":"Kuching","zip":"93586","country":"Malaysia","geoPoint":{"lat":1.55,"lon":110.33333}},{"facility":"Institut Kanser Negara","status":"RECRUITING","city":"Putrajaya","zip":"62250","country":"Malaysia","geoPoint":{"lat":2.93527,"lon":101.69112}},{"facility":"Columbia Asia Hospital Bukit Rimau","status":"RECRUITING","city":"Shah Alam","zip":"40460","country":"Malaysia","geoPoint":{"lat":3.08507,"lon":101.53281}},{"facility":"The Netherlands Cancer Institute - Antoni van Leeuwenhoek","status":"RECRUITING","city":"Amsterdam","state":"North Holland","zip":"1066 CX","country":"Netherlands","geoPoint":{"lat":52.37403,"lon":4.88969}},{"facility":"Med-Polonia Sp. Z o.o.","status":"RECRUITING","city":"Poznan","zip":"60-693","country":"Poland","geoPoint":{"lat":52.40692,"lon":16.92993}},{"facility":"ULS do Alto Ave, EPE - Hospital da Senhora da Oliveira Guimarães","status":"RECRUITING","city":"Guimarães","zip":"4835-044","country":"Portugal","geoPoint":{"lat":41.44443,"lon":-8.29619}},{"facility":"Hospital Santo António dos Capuchos - Unidade Local de Saúde de São José","status":"RECRUITING","city":"Lisbon","zip":"1169-050","country":"Portugal","geoPoint":{"lat":38.72509,"lon":-9.1498}},{"facility":"Instituto Português de Oncologia de Porto Francisco Gentil, E.P.E.","status":"RECRUITING","city":"Porto","zip":"4200-072","country":"Portugal","geoPoint":{"lat":41.1485,"lon":-8.61097}},{"facility":"NEXT Oncology-Hospital Quirónsalud Barcelona","status":"RECRUITING","city":"Barcelona","zip":"08023","country":"Spain","geoPoint":{"lat":41.38879,"lon":2.15899}},{"facility":"Hospital Universitario Vall d'Hebrón","status":"RECRUITING","city":"Barcelona","zip":"08035","country":"Spain","geoPoint":{"lat":41.38879,"lon":2.15899}},{"facility":"Hospital Clinic i Provincial de Barcelona","status":"RECRUITING","city":"Barcelona","zip":"08036","country":"Spain","geoPoint":{"lat":41.38879,"lon":2.15899}},{"facility":"Hospital Universitario Reina Sofia","status":"RECRUITING","city":"Córdoba","zip":"14004","country":"Spain","geoPoint":{"lat":37.89155,"lon":-4.77275}},{"facility":"Institut Català d'Oncolgia de Girona","status":"RECRUITING","city":"Girona","zip":"17007","country":"Spain","geoPoint":{"lat":41.98311,"lon":2.82493}},{"facility":"Hospital Clínico San Carlos","status":"RECRUITING","city":"Madrid","zip":"28040","country":"Spain","geoPoint":{"lat":40.4165,"lon":-3.70256}},{"facility":"START MADRID-Hospital Fundacion Jimenez Diaz","status":"RECRUITING","city":"Madrid","zip":"28040","country":"Spain","geoPoint":{"lat":40.4165,"lon":-3.70256}},{"facility":"Hospital Universitario La Paz","status":"RECRUITING","city":"Madrid","zip":"28046","country":"Spain","geoPoint":{"lat":40.4165,"lon":-3.70256}},{"facility":"NEXT Oncology-Hospital Quirónsalud Madrid","status":"RECRUITING","city":"Madrid","zip":"28223","country":"Spain","geoPoint":{"lat":40.4165,"lon":-3.70256}},{"facility":"Hospital Universitario Virgen del Rocío","status":"RECRUITING","city":"Seville","zip":"41013","country":"Spain","geoPoint":{"lat":37.38283,"lon":-5.97317}},{"facility":"Hospital Universitario Y Politécnico La Fe","status":"RECRUITING","city":"Valencia","zip":"46026","country":"Spain","geoPoint":{"lat":39.47391,"lon":-0.37966}},{"facility":"Changhua Christian Hospital","status":"RECRUITING","city":"Changhua","zip":"500","country":"Taiwan","geoPoint":{"lat":24.0692,"lon":120.5512}},{"facility":"Kaohsiung Medical University Chung-Ho Memorial Hospital","status":"RECRUITING","city":"Kaohsiung City","zip":"807","country":"Taiwan","geoPoint":{"lat":22.61626,"lon":120.31333}},{"facility":"National Cheng Kung University Hospital","status":"RECRUITING","city":"Tainan","zip":"704","country":"Taiwan","geoPoint":{"lat":22.99083,"lon":120.21333}}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-02-25"},"conditionBrowseModule":{"meshes":[{"id":"D002289","term":"Carcinoma, Non-Small-Cell Lung"}],"ancestors":[{"id":"D002283","term":"Carcinoma, Bronchogenic"},{"id":"D001984","term":"Bronchial Neoplasms"},{"id":"D008175","term":"Lung Neoplasms"},{"id":"D012142","term":"Respiratory Tract Neoplasms"},{"id":"D013899","term":"Thoracic Neoplasms"},{"id":"D009371","term":"Neoplasms by Site"},{"id":"D009369","term":"Neoplasms"},{"id":"D008171","term":"Lung Diseases"},{"id":"D012140","term":"Respiratory Tract Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"D016190","term":"Carboplatin"},{"id":"D000068437","term":"Pemetrexed"},{"id":"C582435","term":"pembrolizumab"}],"ancestors":[{"id":"D056831","term":"Coordination Complexes"},{"id":"D009930","term":"Organic Chemicals"},{"id":"D006147","term":"Guanine"},{"id":"D007042","term":"Hypoxanthines"},{"id":"D011688","term":"Purinones"},{"id":"D011687","term":"Purines"},{"id":"D006574","term":"Heterocyclic Compounds, 2-Ring"},{"id":"D000072471","term":"Heterocyclic Compounds, Fused-Ring"},{"id":"D006571","term":"Heterocyclic Compounds"},{"id":"D005971","term":"Glutamates"},{"id":"D024342","term":"Amino Acids, Acidic"},{"id":"D000596","term":"Amino Acids"},{"id":"D000602","term":"Amino Acids, Peptides, and Proteins"},{"id":"D000600","term":"Amino Acids, Dicarboxylic"}]}},"hasResults":false},
{"protocolSection":{"identificationModule":{"nctId":"NCT05297903","orgStudyIdInfo":{"id":"UPCC 17221"},"secondaryIdInfos":[{"id":"IRB#850515","type":"OTHER","domain":"University of Pennsylvania IRB"}],"organization":{"fullName":"Abramson Cancer Center at Penn Medicine","class":"OTHER"},"briefTitle":"XmAb20717 in Advanced Biliary Tract Cancers","officialTitle":"Phase II Trial of XmAb20717 in Patients With Advanced Biliary Tract Cancers"},"statusModule":{"statusVerifiedDate":"2025-09","overallStatus":"ACTIVE_NOT_RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2022-04-11","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2026-12-02","type":"ESTIMATED"},"completionDateStruct":{"date":"2026-12-02","type":"ESTIMATED"},"studyFirstSubmitDate":"2022-02-17","studyFirstSubmitQcDate":"2022-03-17","studyFirstPostDateStruct":{"date":"2022-03-28","type":"ACTUAL"},"lastUpdateSubmitDate":"2025-09-11","lastUpdatePostDateStruct":{"date":"2025-09-15","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Abramson Cancer Center at Penn Medicine","class":"OTHER"},"collaborators":[{"name":"Xencor, Inc.","class":"INDUSTRY"}]},"oversightModule":{"oversightHasDmc":false,"isFdaRegulatedDrug":true,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"This is a single-arm, phase II clinical trial to evaluate the efficacy of XmAb20717 in patients with advanced biliary tract cancers who have progressed on, or were intolerant of, a gemcitabine-based chemotherapy regimen."},"conditionsModule":{"conditions":["Biliary Tract Cancer"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE2"],"designInfo":{"allocation":"NA","interventionModel":"SINGLE_GROUP","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":27,"type":"ESTIMATED"}},"armsInterventionsModule":{"armGroups":[{"label":"XmAb20717","type":"EXPERIMENTAL","description":"Study participants will receive the recommended phase II dose (10mg/kg) of XmAb20717 by intravenous infusion on days 1 and 15 of a 28-day cycle for up to 2 years.","interventionNames":["Drug: XmAb20717"]}],"interventions":[{"type":"DRUG","name":"XmAb20717","description":"10mg/kg IV","armGroupLabels":["XmAb20717"],"otherNames":["ANTI-PD1 × ANTI-CTLA4 BISPECIFIC MONOCLONAL ANTIBODY"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Objective Response Rate (ORR)","description":"Proportion of participants with the best response being complete response (CR) or partial response (PR)","timeFrame":"From therapy initiation, assessed at each restaging scan, for up to 24 months"}],"secondaryOutcomes":[{"measure":"Progression-free survival","description":"Time from study enrollment until disease progression or death with censoring for loss to follow up","timeFrame":"From therapy initiation until progression or death, whichever comes first, for up to 60 months"},{"measure":"Overall survival","description":"Time from study enrollment until death","timeFrame":"From therapy initiation until death, for up to 60 months"},{"measure":"Objective Response Rate (ORR) in patients that received prior immunotherapy","description":"Proportion of participants with the best response being complete response (CR) or partial who received prior immunotherapy.","timeFrame":"From therapy initiation, assessed at each restaging scan, for up to 24 months"},{"measure":"Objective Response Rate (ORR) in patients who did not received prior immunotherapy","description":"Proportion of participants with the best response being complete response (CR) or partial who did not receive prior immunotherapy.","timeFrame":"From therapy initiation, assessed at each restaging scan, for up to 24 months"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Provision of signed and dated informed consent form\n2. Stated willingness to comply with all study procedures and availability for the duration of the study\n3. Male or female, aged \\> 18 years of age\n4. Patient must have advanced biliary tract cancers (BTC) including intrahepatic, perihepatic, or extrahepatic cholangiocarcinoma or gallbladder carcinoma with histologic or cytologic confirmation who have experienced progression, or intolerance of, systemic therapy with a gemcitabine-based regimen.\n5. Patients with tumors harboring an FGFR2 fusion, NTRK fusion, or IDH1 mutation must have received molecularly targeted therapy unless contraindicated or refused. Patients without sequencing results for FGFR2 fusions, NTRK fusions, or IDH1 mutations at the time of screening are permitted to enroll in the study. If sequencing results demonstrating FGFR2 fusions, NTRK fusions, or IDH1 mutations become available after patients have enrolled on the study, patients will be informed of the results and available treatment options but may continue study treatment if they are deriving clinical benefit\n6. ECOG performance status of 0 or 1.\n7. Measurable or evaluable disease as defined by RECIST v. 1.1.\n8. Available archival tissue or willingness to undergo biopsy during the screening period; this requirement can be waived if biopsy deemed infeasible or unsafe by the principal investigator.\n9. For females of reproductive potential: Must have a negative serum pregnancy test performed within 7 days of first study treatment and must agree to use such a method during study participation and for an additional 3 months after the last study dose of XmAb20717. Reproductive potential is defined in section 8.2.11.\n10. For males of reproductive potential with female partners of reproductive potential (per section 8.2.11): Must use of condoms or other methods to ensure effective contraception with partner during the study and for an additional 4 weeks after the end of XmAb20717 administration as outlined in section 8.2.11. Male subjects must agree not to donate sperm from screening through 4 weeks after completion of study\n11. Must have adequate organ and hematopoietic function within 14 days of the start of study treatment as defined in Table 1. Labs from cycle 1 day 1 may be used for eligibility.\n\nExclusion Criteria:\n\n1. Any concurrent condition requiring the continued or anticipated use of systemic steroids beyond physiologic replacement dosing (excluding non-systemic inhaled, topical skin, nasal, and/or ophthalmic corticosteroids). All other systemic corticosteroids above physiologic replacement dosing must be discontinued at least four weeks prior to first study treatment.\n2. Treatment with another investigational drug or other intervention within four weeks prior to the first study treatment date.\n3. Treatment with trans-arterial liver embolization, hepatic arterial infusion, or radiation doses of \\> 30 Gy within 4 weeks prior to the first study treatment date\n4. Treatment with chemotherapy within 3 weeks prior to the first study treatment date\n5. History of permanent discontinuation of a PD-1 or PD-L1 inhibitor therapy due to an immune related adverse event.\n6. Prior treatment with a CTLA-4 inhibitor\n7. Pregnant or breastfeeding\n8. Known allergic reactions to study drug components.\n9. Active brain metastases. Patients with brain metastases must have stable neurological status following local therapy (surgery or radiation) for at least four weeks prior to first study treatment and must be off steroids related to the brain metastases.\n\n   for at least two weeks prior to study treatment.\n10. Active drug or alcohol use or dependence as documented in the chart that, in the opinion of the investigator, would interfere with adherence to study requirements.\n11. Active bacterial, viral, parasitic, or fungal infection requiring IV therapy within 2 weeks of the start of protocol treatment.\n12. A secondary primary malignancy that, in the judgment of the investigator, may affect the interpretation of results.\n13. Prior organ allograft or allogeneic bone marrow transplantation.\n14. A history of, or active, pneumonitis or interstitial lung disease.\n15. Active autoimmune disease. Patients with vitiligo, type 1 diabetes mellitus, endocrinopathies manageable by hormone replacement, and psoriasis not requiring systemic treatment are permitted to enroll. Other autoimmune conditions may be allowable at the discretion of the principal investigator.\n16. Receipt of a live-virus vaccine within 30 days prior to first dose of study drug (seasonal flu and COVID-19 vaccines are permitted, as long as they do not contain live virus and are not administered within 24 hours of planned administration of XmAb20717)\n17. Known human immunodeficiency virus (HIV) infection with CD4+ T-cell (CD4+) counts \\< 350 cells/μL, or an HIV viral load greater than 400 copies/mL, or a history of an acquired immunodeficiency syndrome (AIDS)-defining opportunistic infection within the past 12 months, or who has not been on established antiretroviral therapy (ART) for at least 4 weeks prior to initiation of study drug dosing. (Effective ART is defined as a drug, dosage, and schedule associated with reduction and control of the viral load. HIV positive subjects who do not meet any of these exclusion criteria are eligible.)\n18. Any serious or uncontrolled medical or psychiatric disorder that, in the opinion of the investigator, would prevent the patient from providing informed consent, may increase the risk associated with study participation or study drug administration, impair the ability of the patient to receive study protocol therapy, or interfere with the interpretation of the study results.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Mark O'Hara, MD","affiliation":"Abramson Cancer Center at Penn Medicine","role":"PRINCIPAL_INVESTIGATOR"}],"locations":[{"facility":"Abramson Cancer Center at University of Pennsylvania","city":"Philadelphia","state":"Pennsylvania","zip":"19104","country":"United States","geoPoint":{"lat":39.95238,"lon":-75.16362}}]},"ipdSharingStatementModule":{"ipdSharing":"NO"}},"documentSection":{"largeDocumentModule":{"largeDocs":[{"typeAbbrev":"Prot_SAP","hasProtocol":true,"hasSap":true,"hasIcf":false,"label":"Study Protocol and Statistical Analysis Plan","date":"2024-10-24","uploadDate":"2024-12-13T14:37","filename":"Prot_SAP_001.pdf","size":1660577}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-02-25"},"conditionBrowseModule":{"meshes":[{"id":"D001661","term":"Biliary Tract Neoplasms"}],"ancestors":[{"id":"D004067","term":"Digestive System Neoplasms"},{"id":"D009371","term":"Neoplasms by Site"},{"id":"D009369","term":"Neoplasms"},{"id":"D001660","term":"Biliary Tract Diseases"},{"id":"D004066","term":"Digestive System Diseases"}]}},"hasResults":false},
{"protocolSection":{"identificationModule":{"nctId":"NCT07284797","orgStudyIdInfo":{"id":"XmAb657-01"},"organization":{"fullName":"Xencor, Inc.","class":"INDUSTRY"},"briefTitle":"A Phase 1 Open-label Study to Evaluate Safety in Healthy Participants and Participants With Idiopathic Inflammatory Myopathy (IIM)","officialTitle":"A Phase 1, First-in-Human, Open-Label, Dose-Escalation Study to Evaluate the Safety and Tolerability, Pharmacokinetics, and Pharmacodynamics of XmAb657 in Healthy Participants and in Participants With Idiopathic Inflammatory Myopathy"},"statusModule":{"statusVerifiedDate":"2025-12","overallStatus":"NOT_YET_RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2026-02","type":"ESTIMATED"},"primaryCompletionDateStruct":{"date":"2027-02","type":"ESTIMATED"},"completionDateStruct":{"date":"2027-02","type":"ESTIMATED"},"studyFirstSubmitDate":"2025-12-03","studyFirstSubmitQcDate":"2025-12-15","studyFirstPostDateStruct":{"date":"2025-12-16","type":"ACTUAL"},"lastUpdateSubmitDate":"2025-12-15","lastUpdatePostDateStruct":{"date":"2025-12-16","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Xencor, Inc.","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":true,"isFdaRegulatedDrug":false,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"The purpose of this study is to determine the safety and tolerability of XmAb657 in healthy participants and participants with IIM. Participants will be given XmAb657 subcutaneously (SC) by injection under the skin.","detailedDescription":"This is a Phase 1 study to determine the safety, tolerability, pharmacokinetic (PK), and pharmacodynamics (PD), and immunogenicity of XmAb657 in healthy adult participants and participants with IIM."},"conditionsModule":{"conditions":["Healthy","Idiopathic Inflammatory Myopathies"],"keywords":["Myopathy","Myositis"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE1"],"designInfo":{"allocation":"NA","interventionModel":"SINGLE_GROUP","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":27,"type":"ESTIMATED"}},"armsInterventionsModule":{"armGroups":[{"label":"Dose Escalation","type":"EXPERIMENTAL","description":"XmAb657 administered SC","interventionNames":["Biological: XmAb13676"]}],"interventions":[{"type":"BIOLOGICAL","name":"XmAb13676","description":"Biological","armGroupLabels":["Dose Escalation"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Percentage of participants with treatment emergent adverse events (TEAEs) and serious adverse events (SAEs)","timeFrame":"Through Week 24"}],"secondaryOutcomes":[{"measure":"Serum concentration of XmAb657","timeFrame":"Through Week 24"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\nHealthy participants - Adult participants in good health\n\nIdiopathic inflammatory myopathy participants - Adult participants that meet the 2017 European Alliance of Association Rheumatology (EULAR)/American College of Rheumatology (ACR) classification of Idiopathic inflammatory myopathy\n\nIdiopathic inflammatory myopathy participants - Stable doses of Idiopathic inflammatory myopathy medications prior to screening\n\nAll participants - Use of highly effective methods of contraception\n\nExclusion Criteria:\n\n* Major surgery within 12 weeks prior to screening or planned within 12 months after dosing\n* Recurrent infections or active clinically significant infection\n* Active or untreated latent tuberculosis\n* Cancer or history of cancer or lymphoproliferative disease within the previous 5 years\n* Uncontrolled cardiovascular, pulmonary, renal, hepatic, endocrine, or gastrointestinal disease\n\nNote: Additional, more specific inclusion/exclusion criteria are defined in the protocol.","healthyVolunteers":true,"sex":"ALL","minimumAge":"18 Years","maximumAge":"75 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"centralContacts":[{"name":"Noriko Iikuni, MD, PhD","role":"CONTACT","email":"657-AIinfo@xencor.com"},{"name":"Jaime Mertz","role":"CONTACT","email":"657-AIinfo@xencor.com"}],"overallOfficials":[{"name":"Mark Osterman, MD, MSCE","affiliation":"Xencor, Inc.","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"Xencor Investigative Site","city":"Melbourne","country":"Australia","geoPoint":{"lat":-37.814,"lon":144.96332}}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-02-25"},"conditionBrowseModule":{"meshes":[{"id":"D009220","term":"Myositis"},{"id":"D009135","term":"Muscular Diseases"}],"ancestors":[{"id":"D009140","term":"Musculoskeletal Diseases"},{"id":"D009468","term":"Neuromuscular Diseases"},{"id":"D009422","term":"Nervous System Diseases"}]}},"hasResults":false}
]}